CMPX · Compass Therapeutics, Inc. · Executive Compensation
$0.67
-0.01 (-1.25%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$122.19M
Shares
180.09M
Volume · Nov 19
1.68M
Avg daily vol (3M)
3.86M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | MD., Ph.D. Chief Executive Officer | $5,097,150 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $1,427,800 |
| Barry Shin | Chief Financial Officer | $1,394,500 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vered Bisker-Leib | Ph.D., MBA Formerly Chief Executive Officer | $6,433,665 |
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $3,093,057 |
| Barry Shin | Chief Financial Officer | $1,220,942 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $893,635 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $4,873,206 |
| Vered Bisker-Leib | Ph.D., MBA Formerly Chief Executive Officer | $4,067,284 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $707,948 |
| Barry Shin | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. President of Research & Development (formerly CEO) | $2,115,185 |
| Vered Bisker-Leib | Ph.D., MBA Chief Executive Officer (formerly President and COO) | $1,724,739 |
| Susan Kalled | Chief Scientific Officer | $462,030 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $5,258,000 |
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $4,450,000 |
| Susan Kalled | Chief Scientific Officer | $1,781,616 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $2,571,579 |
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $2,556,793 |
| Susan Kalled | Chief Scientific Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $1,373,843 |
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $1,055,034 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Neil Lerner | principal accounting officer | Appointed | 2024-12-10 |
| Barry Shin | Chief Financial Officer | Appointed | 2024-12-10 |
| Thomas Schuetz | President and Chief Executive Officer (Principal Executive Officer, Principal Financial and Principal Accounting Officer) | Appointed | 2024-05-28 |
|
Vered Bisker-Leib
“Dr. Bisker-Leib’s resignation from the Board of Directors is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2024-05-28 |
|
Vered Bisker-Leib
“Dr. Bisker-Leib’s resignation from the Board of Directors is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) | Resigned | 2024-05-28 |
| Vered Bisker-Leib, PhD | member of the Board | Appointed | 2024-01-09 |
| Vered Bisker-Leib, PhD | Chief Executive Officer | Appointed | 2024-01-09 |
| Richard S. Lindahl | member and chairman of the Company's Audit Committee | Appointed | 2023-04-24 |
| Richard S. Lindahl | Class III director | Appointed | 2023-04-24 |
|
David Wurzer
“Mr. Wurzer’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-02-24 |
| David Wurzer | Class III director | Appointed | 2023-02-10 |
|
Stephen Squinto, Ph.D.
“Dr. Squinto’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2022-08-19 |
| Mary Ann Gray | director | Appointed | 2022-04-26 |
| Ellen Chiniara | director | Appointed | 2022-04-26 |
|
Julie Sunderland
“Ms. Sunderland’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2021-12-21 |
| Miranda Toledano | Class II director | Appointed | 2021-06-30 |
Leadership
- Thomas J. Schuetz CEO, Board Member
- Thomas Schuetz CEO, Board Member
- Thomas Schuetz, MD, PhD CEO, Chairman
- Vered Bisker-Leib, PhD CEO, Board Member
- Barry Shin CFO
- Dr. Bisker-Leib COO
- Vered Bisker-Leib COO
- Jonathan E. Anderman General Counsel
- Neil Lerner Chief Accounting Officer
- Brett Kaplan, M.D. Board Member
- David Wurzer Board Member
- Ellen Chiniara Board Member
- Miranda Toledano Board Member
- Phil Ferneau Board Member
- Richard S. Lindahl Board Member
- Steven Squinto Board Member
Key facts
CIK
1738021
CUSIP
20454B104
13F (30d)
187 filings
169 filers
Visit website
Investor relations